Findings regarding CXCL9
Stevens AJ, et al. The role of public-sector research in the discovery of drugs and vaccines. N Engl J Med 2011; 364:535–541. doi: 10.1056/NEJMsa1008268
Cavanaugh C, Perazella MA. Urine sediment examination in the diagnosis and management of kidney disease: Core curriculum 2019. Am J Kidney Dis 2019; 73:258–272. doi: 10.1053/j.ajkd.2018.07.012
Moledina DG, et al. Identification and validation of urinary CXCL9 as a biomarker for diagnosis of acute interstitial nephritis. J Clin Invest 2023; 133:e168950. doi: 10.1172/JCI168950
Müller M, et al. Review: The chemokine receptor CXCR3 and its ligands CXCL9, CXCL10 and CXCL11 in neuroimmunity—a tale of conflict and conundrum. Neuropathol Appl Neurobiol 2010; 36:368–387. doi: 10.1111/j.1365-2990.2010.01089.x
Jackson JA, et al. Urinary chemokines CXCL9 and CXCL10 are noninvasive markers of renal allograft rejection and BK viral infection. Am J Transplant 2011; 11:2228–2234. doi: 10.1111/j.1600-6143.2011.03680.x